Harley-Davidson Stock To Go Ex-dividend Tomorrow (HOG)

NEW YORK ( TheStreet) -- The ex-dividend date for Harley-Davidson (NYSE: HOG) is tomorrow, February 14, 2014. Owners of shares as of market close today will be eligible for a dividend of 28 cents per share. At a price of $64.62 as of 9:50 a.m. ET, the dividend yield is 1.7%.

The average volume for Harley-Davidson has been 1.2 million shares per day over the past 30 days. Harley-Davidson has a market cap of $14.3 billion and is part of the consumer goods sector and automotive industry. Shares are down 5.9% year to date as of the close of trading on Wednesday.

Harley-Davidson, Inc. manufactures heavyweight cruiser and touring motorcycles. The company operates through two segments: the Motorcycles segment and the Financial Services segment.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Harley-Davidson as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Harley-Davidson Ratings Report.

See our dividend calendar or top-yielding stocks list.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing